Cancer Vaccine

Chaperone-rich tumor cell lysates show promise

Published in Blood Weekly, May 1st, 2003

by Michael Greer, senior medical writer - Tumor-derived chaperone-rich cell lysates (CRCL) could be the basis for an effective anti-cancer vaccine, researchers in the United States say.

Yi Zeng and colleagues at the University of Arizona assessed the immunogenicity of CRCL-pulsed dendritic cells (DCs) in a murine leukemia model.

CRCL-based immunization conferred potent and durable protection, and demonstrated therapeutic effects as well, they found.

The researchers used 12B1 tumor cells to generate CRCL fractions, which were then used to incubate carrier DCs. 12B1 is an "aggressive bcr-abl positive murine leukemia,"...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-05-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry